The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo-Reference-Cited by-同舟云学术

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo

Published:2023-03 Issue: Volume:170 Page:172-178
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Han Chanhee,McNamara Blair,Bellone Stefania,Harold Justin,Manara Paola,Hartwich Tobias Max Philipp,Mutlu Levent,Yang-Hartwich Yang,Zipponi Margherita,Demirkiran Cem,Verzosa Miguel Skyler Z.,Altwerger Gary,Ratner Elena,Huang Gloria S.,Clark Mitchell,Andikyan Vaagn,Azodi Masoud,Dottino Peter R.,Schwartz Peter E.,Santin Alessandro D.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference46 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J. Clin.,2018

2. Cancer of the ovary;Cannistra;N. Engl. J. Med.,2004

3. Targeting the double-strand DNA break repair pathway as a therapeutic strategy;Lord;Clin. Cancer Res.,2006

4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial;Audeh;Lancet.,2010

5. LBA40_PRARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC);Ledermann;Ann. Oncol.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib plays synergistic antitumor effects with NRT in a mouse ovarian cancer model with HRP;Translational Oncology;2024-11

2. Navigating immunotherapy for ovarian cancer: current landscape and future perspectives;Journal of Cancer Metastasis and Treatment;2024-06-26